Regulus Therapeutics
RGLS
#6949
Rank
NZ$0.97 B
Marketcap
NZ$14.12
Share price
0.00%
Change (1 day)
446.62%
Change (1 year)

Regulus Therapeutics (RGLS) - Cash on Hand

Cash on Hand as of March 2025 : NZ$0.11 Billion

According to Regulus Therapeutics's latest financial reports the company has NZ$0.11 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Regulus Therapeutics - Cash on Hand chart (from 2011 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31NZ$0.13 B257.52%
2023-12-31NZ$37.58 M-39.07%
2022-12-31NZ$61.67 M-30.23%
2021-12-31NZ$88.4 M105.19%
2020-12-31NZ$43.08 M-14.96%
2019-12-31NZ$50.66 M143.87%
2018-12-31NZ$20.77 M-75.44%
2017-12-31NZ$84.58 M-23.02%
2016-12-31NZ$0.10 B-34.07%
2015-12-31NZ$0.16 B-18.26%
2014-12-31NZ$0.20 B46.96%
2013-12-31NZ$0.13 B16.34%
2012-12-31NZ$0.11 B144%
2011-12-31NZ$48.87 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
GlaxoSmithKline
GSK
NZ$7.69 B 6,699.01%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
NZ$18.09 B 15,889.32%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
NZ$6.85 B 5,958.62%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$14.16 B 12,416.83%๐Ÿ‡ฌ๐Ÿ‡ง UK
Alnylam Pharmaceuticals
ALNY
NZ$4.71 B 4,068.13%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
NZ$51.26 M-54.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$28.56 B 25,144.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA